Filing Flows › Crispr Therapeutics AG (CRSP) › Q2 2026 › vs Q1 2026
Crispr Therapeutics AG (CRSP) Q2 2026 vs Q1 2026 (quarter over quarter)
Crispr Therapeutics AG's revenue rose $8.7M (+598%) from $1.5M in Q1 2026 to $10.2M in Q2 2026. The biggest changes: Collaboration Revenue +$9.0M (+900%); Grant −$277K (-60%).
Crispr Therapeutics AG, Q2 2026: revenue $10.2M (11× year over year), net loss $91.2M, operating cash flow −$83.5M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Collaboration Revenue | $10.0M | $1.0M | $9.0M | +900% |
| Grant | $181K | $458K | −$277K | -60% |
| Revenue | $10.2M | $1.5M | $8.7M | +598% |
| Other income, net | $27.1M | $8.2M | $18.9M | +232% |
| Net loss | $91.2M | $123M | −$31.8M | -26% |
| Costs & expenses | $128M | $133M | −$4.1M | -3% |
| Operating costs | $127M | $132M | −$4.3M | -3% |
| Income tax | $960K | $839K | $121K | +14% |
| Research & development | $67.2M | $68.6M | −$1.4M | -2% |
| General & admin | $17.6M | $17.2M | $370K | +2% |
| Other operating costs | $42.7M | $45.9M | −$3.2M | -7% |
| Operating cash sources | $105M | $130M | −$24.4M | -19% |
| Depreciation & amortization | $4.3M | $4.3M | −$39K | -0.9% |
| Share-based compensation | $17.3M | $16.3M | $992K | +6% |
| Cash used in operations | $83.5M | $109M | −$25.4M | -23% |
| Net loss absorbed | $91.2M | $123M | −$31.8M | -26% |
| Working capital & other | $13.9M | $6.6M | $7.3M | +111% |
Questions
How much did Crispr Therapeutics AG's revenue grow quarter over quarter in Q2 2026?
Crispr Therapeutics AG's revenue rose $8.7M (+598%) from $1.5M in Q1 2026 to $10.2M in Q2 2026.
What drove Crispr Therapeutics AG's revenue change in Q2 2026?
Collaboration Revenue +$9.0M (+900%); Grant −$277K (-60%).